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eral vascular and coronary revascularization procedures.2,4
In addition, diabetic patients experience greater rates of
intimal hyperplasia (IH) as manifested by increased
restenosis after coronary angioplasty and increased failure
of dialysis access grafts.5,6 This increased intimal hyper-
plastic activity may reflect abnormalities of diabetic vascu-
lar smooth muscle cells (VSMCs) of venous origin. These
observations suggest that VSMCs behave in a phenotypi-
cally different and more aggressive proatherogenic manner
in patients with diabetes. The purpose of this study was to
examine the in vitro rates of proliferation, adhesion, and
migration of human VSMCs obtained from diabetic and
nondiabetic patients and to determine if differences intrin-
sic to the DM-VSMC phenotype could be identified.
METHODS
Patients and specimens. Vascular biopsies were
obtained at the time of surgery from 38 patients (23 dia-
betic, 15 nondiabetic). All specimens were obtained under
experimental protocol approved by the Institutional
Review Board of the Beth Israel Deaconess Medical
Center/Harvard Medical School (#98-84E). Arterial vas-
cular specimens were obtained at the time of amputation
Diabetes mellitus (DM) affects between 20 and 25
million patients in the United States with an estimated
annual cost of more than $50 billion.1,2 Diabetes has been
established as an independent risk factor for atherosclero-
sis.3 Patients with diabetes experience progressive
macrovascular atherosclerosis, and as a result diabetic
patients account for a significant proportion of all periph-
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Purpose: Patients with diabetes mellitus (DM) experience progressive macrovascular atherosclerosis and intimal hyper-
plastic restenosis with increased frequency as compared with nondiabetic patients. These observations suggest that vas-
cular smooth muscle cells (VSMCs) behave in a phenotypically different and more aggressive manner in diabetic
patients. In this study, we compared the in vitro rates of proliferation, adhesion, and migration of human VSMCs
obtained from diabetic and nondiabetic patients.
Methods: Human VSMC cultures were isolated from 23 diabetic patients (9 artery, 14 vein) and 15 nondiabetic patients
(9 artery, 6 vein) with extensive lower extremity atherosclerosis. All patients were between 61 and 78 years of age (aver-
age: 68.4 years [diabetic]; 67.3 years [nondiabetic]). All diabetic patients had type 2 DM. Vascular specimens were
obtained at the time of amputation from infragenicular arteries and during arterial revascularization from saphenous
veins. Cells from passages 2 and 3 were assayed for their proliferative capacity with total DNA fluorescence photome-
try and for adhesion and migration with a modified Boyden chamber.
Results: The average duration of diabetes was 11.6 ± 4.1 years. The average number of diabetic complications (retinopa-
thy, neuropathy, nephropathy, coronary artery disease) was 2.8 ± 0.7 per patient. Diabetic VSMCs exhibited abnormal
morphology in cell culture with loss of the normal hill and valley configuration. Proliferation was significantly
increased in VSMCs of diabetic origin (156 ± 57 absorption units) as compared with those of nondiabetic origin (116
± 42 absorption units) (P < .001). Diabetic VSMCs demonstrated significantly greater adhesion (63.6 ± 24 per high-
power field vs 37.9 ± 13 per high-power field; P = .002) and migration (397 ± 151 per low-power field vs 121 ± 99
per low-power field; P = .001) rates.
Conclusions: Diabetic VSMCs exhibit significantly increased rates of proliferation, adhesion, and migration as well as
abnormal cell culture morphology suggestive of abnormal contact inhibition. These observations of human VSMCs in
culture are consistent with the increased rate of infragenicular atherosclerosis and the increased rates of restenosis
observed clinically in diabetic patients. The atherosclerosis- and intimal hyperplasia–promoting behavior exhibited
appears to be intrinsic to the DM-VSMC phenotype and must be considered when designing methods to limit athero-
sclerosis and intimal hyperplasia in diabetic patients. (J Vasc Surg 2001;33:601-7.)
from infragenicular arteries. Saphenous vein specimens
were obtained during arterial revascularization (Table).
VSMCs obtained from nondiabetic patients served as con-
trols for comparison with diabetic VSMCs. All assays were
performed on cells derived from distinct, individual speci-
mens. Cell lines were not mixed in the analysis. Clinical
patient characteristics, including age, duration of diabetes,
insulin requirement, number of secondary complications
of diabetes, medical comorbidity, and risk factors for ath-
erosclerosis, were recorded.
VSMC cultures. Cultures were initiated from each
specimen immediately after explantation. Primary VSMC
cultures were isolated after removal of the adventitia and
scraping of the endothelium. Arterial strips were then
incubated in Dulbecco modified Eagle medium (DMEM)
(Gibco, Life Technologies, Rockville, Md), with 10% fetal
bovine serum (FBS) (Gibco), 1% penicillin/strepto-
mycin/amphotericin B (Gibco), and 1 mol/L HEPES
(Gibco) at 37°C in 5% carbon dioxide humidified atmo-
sphere. VSMCs were also propagated in DMEM with 10%
FBS in subsequent passages. The mean incubation time
was 7.3 days. Cell viability was confirmed with trypan blue
exclusion after each passage and assay. All assays were con-
ducted with subconfluent cells from passages 2 and 3.
VSMC type was confirmed in culture by positive immuno-
labeling with anti–smooth muscle cell α-actin (mouse
monoclonal anti–smooth muscle cell α-actin (clone 1A4)
(Neomarkers, Union City, Calif), 1:200 (V/ V) with
biotinylated horse antimouse immunoglobulin G (H+L)
(Vector Laboratories, Burlingame, Calif), 1:100 (V/ V)
(Fig 1).
Proliferation assay. VSMCs were detached with
trypsin-EDTA (Gibco) and replated at a density of 10,000
cells per well. VSMCs were then serum starved in DMEM
with 1% FBS for 24 hours to synchronize cell cycles.
VSMCs were incubated in DMEM with 10% FBS for 72
hours. The medium was changed daily to maintain appro-
priate glucose concentration. Cell lysis was performed with
0.05% sodium dodecyl sulfate. DNA was labeled with bis-
benzimide (Hoechst, 33258, 1:10,000 (V/ V) (Amersham
Pharmacia Biotech, Piscataway, NJ). Quantification was per-
formed with a filter fluorescence photometer (TKO 100
fixed excitation bandpass source [365 nm] and emission
[460 nm] bandpass filter). This method provides increased
accuracy over tritium-thymidine incorporation. Positive
controls were calf thymus; negative controls were serum-
starved VSMCs, bisbenzimide only. VSMCs from each
specimen were assayed six times, and the results were aver-
aged for each specimen individually.
Adhesion assay. After being maintained in DMEM
with 1% FBS for 24 hours, VSMCs were detached with
trypsin-EDTA (Gibco) and loaded into a modified
Boyden adhesion chamber (Osmonics Laboratory and
Special Products, Livermore, Calif). A total of 1000 cells
were placed into each well that contained a polycarbonate
adhesion membrane (Osmonics). The Boyden chamber
was incubated at 37°C in a 5% carbon dioxide humidified
atmosphere for 2 hours. The adhesion membrane was
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Vessels of origin of vascular specimens
Site of origin Diabetic Nondiabetic
Infragenicular artery 9 9
Saphenous vein 14 6
Fig 1. Photomicrograph of immunohistochemical preparation of anti–smooth muscle cell α actin–labeled VSMCs in
culture. Labeling of actin fibers appears as brown precipitate, confirming that explanted cells are VSMCs in origin.
then removed, washed in phosphate-buffered saline, fixed
with 90% ethanol, and stained with hematoxylin (Fig 2).
Adherent cells were quantified with a digitized video
microscopic image analyzer and calibrated image analysis
software (Jandel Scientific, Corte Madera, Calif). VSMCs
from each specimen were assayed four times, and the
results were averaged for each specimen. Adhesion of
human VSMCs derived from undiseased aortic cell lines
was used for the positive control.
Migration assay. VSMCs assayed for migration were
placed in DMEM with 1% FBS for 24 hours. VSMCs were
detached with trypsin-EDTA (Gibco) and loaded into a
modified Boyden chemotaxis chamber (Corning Costar,
Cambridge, Mass). Migration medium containing
platelet-derived growth factor–BB as a migratory stimulus
at a concentration of 10 ng/mL in DMEM with 10% FBS
was loaded into the reservoir that was separated from the
VSMCs by the migration membrane (8-µm pore size, 6.5-
mm diameter). A total of 10,000 cells were placed in each
well, and the chemotaxis chamber was incubated at 37°C
in a 5% carbon dioxide humidified atmosphere for 4 hours.
After incubation VSMCs were fixed with 70% ethanol and
stained with fluorescein isothiocyanate–conjugated nucleic
acid stain (Sytox, 1:5000 (V/ V), Molecular Probes,
Eugene, Ore). Cells that migrated through the membrane
were quantified with a digitized video microscopic image
analyzer and calibrated image analysis software (Jandel
Scientific). Migration of human VSMCs derived from
undiseased aortic cell lines was used for the positive con-
trol. VSMCs assayed with a migration solution that did
not contain platelet-derived growth factor–BB served as
the negative control. VSMCs from each specimen were
assayed four times, and the results were averaged for each
specimen.
Statistical analysis. Continuous variables were com-
pared with a Student t test. Statistical significance was
assumed at the 95% confidence level (P < .05). Data are
represented as the mean ± SD.
RESULTS
Patient data. The patients’ ages ranged between 61
and 78 years (average: 68.4 years [diabetic]; 67.3 years
[nondiabetic]; P = not significant). All diabetic patients
had type 2 DM. Insulin was required in 85.7%; the
remaining 14.3% were non–insulin dependent. Secondary
complications of diabetes, including retinopathy, neuropa-
thy, nephropathy, and coronary artery disease, were 
present in all patients. The average number of diabetic
complications was 2.8 per patient (range, 1-4 complica-
tions per patient).
Cell culture morphometry. The VSMCs derived
from nondiabetic patients demonstrated the normal hill
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Fig 2. Photomicrograph of VSMCs adherent to polycarbonate adhesion membrane. A, Nondiabetic. Relatively few non-
diabetic VSMCs are adherent to polycarbonate membrane. B, Diabetic. VSMCs of diabetic origin demonstrated adhesion
in significantly greater numbers, indicating greater adhesive capacity. VSMCs have been stained with hematoxylin to allow
quantification with video image analyzer.
A B
and valley morphometry typically observed in VSMCs in
culture. In contrast, VSMCs derived from diabetic patients
exhibited a loss of the hill and valley morphometry and
were densely and continuously packed together in multi-
ple cell layers (Fig 3). The observed loss of normal cell cul-
ture morphometry in the VSMCs of diabetic origin
suggests a loss of normal contact inhibition of migration
and proliferation in these diabetic cells.
Proliferation. Proliferation rates were significantly
increased for VSMCs of diabetic origin. Diabetic VSMCs
had a mean proliferative rate of 156 ± 57 absorption units
as measured with fluorescence photometer. The prolifera-
tive rate of VSMC of nondiabetic origin was 116 ± 42
absorption units (P < .001; Fig 4).
Adhesion. Adhesion as measured by adherence to a
polycarbonate adhesion membrane was significantly
increased in VSMCs of diabetic origin as compared with
nondiabetic VSMCs. The mean number of diabetic adherent
cells was 63.6 ± 24 cells per microscopic field. In contrast,
the mean number of adherent cells of nondiabetic origin was
37.9 ± 13 cells per microscopic field (P = .002; Fig 5).
Migration. Diabetic VSMCs demonstrated signifi-
cantly increased migratory capacity in relation to nondia-
betic cells. The mean number of cells to migrate in the
diabetic cell population was 397 ± 151 cells per micro-
scopic field. This was significantly greater than the rate
observed for the nondiabetic cells (121 ± 99 cells per
microscopic field, P = .001; Fig 6).
DISCUSSION
The increased rate of atherosclerosis and IH experi-
enced by diabetic patients relative to age-matched cohorts
of patients without DM suggests an underlying abnormal-
ity in the biology of VSMCs in diabetic patients. Evidence
of variable phenotypes of VSMCs has been noted by sev-
eral investigators. The greater incidence of atherosclerotic
plaque formation in the abdominal versus the thoracic
aorta has been shown with aortic homograft experiments
in the canine model to result from differences intrinsic to
the VSMC population of those segments of aorta. These
phenotypic differences, in turn, are thought to result from
distinct lineages of the VSMCs from which the segments
of aorta are derived.7 Variation in VSMC phenotype based
on cell lineage has been observed in additional animal
models as well.8 Phenotypic modulation of VSMCs has
also been observed in animal models of IH.7 After expo-
sure to arterial pressure, VSMCs of the conduit vein graft
were altered from differentiated, quiescent type to dedif-
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Fig 3. Photomicrograph of VSMCs in cell culture. A, Nondiabetic. VSMCs of nondiabetic origin demonstrate the nor-
mal hill and valley morphologic appearance in culture, with areas of higher cell density (hill) being separated by areas of
low density (valley). B, Diabetic. VSMCs of diabetic origin fail to demonstrate normal hill and valley morphology. Diabetic
cells are densely packed together with multiple layers of cells superimposed on one another. This appearance suggests loss
of normal contact inhibition of proliferation and migration.
ferentiated, embryonic, and proliferative type.9 These
observations suggest that variation in VSMC phenotype
may result from intrinsic or environmental differences.
Phenotypic variation of VSMCs has also been exam-
ined in human-derived cells. In cell culture, VSMCs
derived from diseased atherosclerotic tibial arteries have
been noted to lose the normal relaxation response to phar-
macologic and physiologic stimuli.10 Altering the culture
environment has significant effects on human VSMCs as
well. Growth and morphologic characteristics of the
VSMCs are altered when they are maintained in coculture
with endothelial cells.11 In addition, the presence of
inflammatory cytokines has been shown to induce trans-
formation from the contractile, quiescent VSMC pheno-
type to the synthetic phenotype in cell culture.12
Factors associated with DM have been implicated in
altering human VSMC phenotype in cell culture. Both
insulin and glucose promote proliferation of VSMCs
derived from infragenicular arteries in culture.13 The pro-
liferative effects of insulin appear to be inhibited by the
addition of transforming growth factor–β1.14 VSMCs in
diabetic resistance vessels have also demonstrated signifi-
cant abnormalities, including augmented vasoconstrictive
response to adrenergic stimuli and impaired relaxation.15
Marked phenotypic differences were observed in this
study between VSMCs derived from the infragenicular
arteries and saphenous veins of diabetic patients and those
derived from nondiabetic patients who were matched for
degree of atherosclerosis and age, as well as other risk fac-
tors for atherosclerosis. These phenotypic differences
included increased proliferative capacity, increased cellular
adhesion and migration, and the loss of normal cell culture
morphology. Cellular proliferation has been widely impli-
cated as being integral to the development of both ather-
osclerosis and IH.16-18 A variety of derangements in the
control of VSMC proliferation have been identified and
associated with increased rates of atherosclerosis and IH.19
The proliferative rate of diabetic VSMCs in this study was
nearly 50% greater than that of nondiabetic VSMCs, a dif-
ference that was highly statistically significant. The
observed increase in proliferative capacity may well con-
tribute to the development of hyperplastic VSMC lesions
in these patients.
The migration of VSMCs from the media to the intima
has been emphasized as a necessary event in the develop-
ment of both IH and atherosclerosis.20-22 In addition,
both overexpression of adhesion molecules in the vessel
wall and increased activation of adhesion kinase have been
implicated in contributing to the development of athero-
sclerosis and IH.23,24 A significant increase in migration
and adhesion was observed in VSMCs of the diabetic phe-
notype in this study. The rate of adhesion for diabetic
VSMCs was nearly double that of nondiabetic VSMCs,
whereas the rate of migration was more than double for the
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Fig 4. Proliferation—diabetic and nondiabetic VSMCs. VSMCs
of diabetic origin demonstrate significantly greater proliferative
capacity than do nondiabetic cells (P < .001).
Fig 5. Adhesion—diabetic and nondiabetic VSMCs. VSMCs of
diabetic origin demonstrate significantly greater adhesion as com-
pared with nondiabetic VSMCs (P = .002).
Fig 6. Migration—diabetic and nondiabetic VSMCs. Again,
VSMCs of diabetic origin demonstrate significantly greater migra-
tion as compared with nondiabetic VSMCs (P = .001).
diabetic-derived cells. Taken in combination with the sig-
nificantly increased rate of proliferation, these abnormali-
ties appear to promote proatherogenic activity in the
VSMCs and are likely to contribute to the increased rate of
atherosclerosis and IH seen in diabetic patients.
Abnormalities of cell culture morphology have been
associated with dysregulation of VSMC physiology in
previous studies.11 These abnormalities appear to result,
in part, from the loss of normal contact inhibition of pro-
liferation and migration of the VSMCs in culture. While
VSMCs derived from nondiabetic arteries and saphenous
veins in this study demonstrated the hill and valley con-
figuration normally seen in VSMC cultures, VSMC cul-
tures derived from diabetic patients exhibited loss of the
hill and valley morphometry. Instead, the diabetic
VSMCs developed multiple layers of densely mixed cells.
These observations serve to further highlight the intrinsic
abnormalities observed in VSMCs of diabetic origin in
this study.
That the differences in proliferation, adhesion,
migration, and culture morphometry seen in this study
occurred in a constant cell culture environment suggests
that the abnormalities are intrinsic to the diabetic VSMC
phenotype. These differences are the likely result of
long-term exposure to circulating factors in the diabetic
patient. Extensive study of the role of advanced glycation
end products has been carried out by numerous investi-
gators.25 It is possible that the accumulation of these
advanced glycation end products may promote the
proatherogenic activities of the VSMCs seen in this
study. In addition, recent investigations have identified
abnormalities of 1,2-diacylglycerol levels and the resul-
tant increased activation of protein kinase C that are
associated with the development of the secondary vascu-
lar complications of diabetes.26 Abnormally increased
diacylglycerol levels and protein kinase C activity may
also be contributing to the abnormalities seen in the
VSMCs in this study.
In conclusion, VSMCs of diabetic origin exhibit sig-
nificantly increased rates of proliferation, adhesion, and
migration, as well as abnormal cell culture morphology
suggestive of abnormal contact inhibition. These observa-
tions of human VSMCs in culture are consistent with the
increased rate of infragenicular atherosclerosis and
increased rates of restenosis observed clinically in diabetic
patients. The atherosclerosis- and IH-promoting behavior
exhibited appears to be intrinsic to the DM-VSMC phe-
notype and must be considered when designing methods
to limit atherosclerosis and IH in diabetic patients.
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